There are 4 parts to this study for which the primary objectives are to evaluate safety,
tolerability, and pharmacokinetics (PK) of navitoclax when administered alone (Part 1) or
when administered in combination with ruxolitinib (Part 2). In Part 2, participants must have
been receiving a stable dose of ruxolitinib therapy for at least 12 weeks prior to study
enrollment. In Part 3, all eligible participants will receive navitoclax, with the primary
objective being to evaluate potential navitoclax effect on QTc prolongation. In Part 4,
effect of navitoclax is evaluated on the PK, safety, and tolerability of a single dose of
celecoxib in participants with myeloproliferative neoplasm (MPN) or chronic myelomonocytic
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.